At 10.3% CAGR, the South & Central America Radiopharmaceutical Theranostics Market is Projected to be worth US$ 233.71 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the South & Central America radiopharmaceutical theranostics market was valued at US$ 129.48 million in 2022 and is expected to reach US$ 233.71 million by 2028, registering a CAGR of 10.3% from 2022 to 2028. Rising incidence of cancer and rising application in treatment of cardiovascular disorders are the critical factors attributed to the South & Central America radiopharmaceutical theranostics market expansion.             

Theranostics in nuclear medicine gathers researchers’ interest through molecular imaging and personalized medicine. This is achieved through assistance in the management of various diseases, improves patient selection process, predicts drug response and toxicity, determines prognosis, and helps avoid futile and costly/expensive examinations and treatments. The theranostic approach to nuclear medicine involves a combination of diagnostic imaging and therapy based on a radioactive drug; its primary focus is the diagnosis, while the secondary focus is the treatment of a tumor site. Radioiodine was the first theranostic radiopharmaceutical used in treating and imaging thyroid diseases. In radioiodine therapy, the radioisotope iodine-131 is a gamma and beta emitter, and the sodium-iodide symporter can directly mediate the gamma emitter to thyroid cells. Further, gamma and positron emitters (β+) are used in nuclear imaging. Gamma emitters such as technetium-99m or iodine-123 are used in SPECT imaging, whereas the use of gallium-68 and fluorine-18 in PET imaging can provide better resolution. Therefore, theranostics-based nuclear-targeted therapies are emerging as a useful tool for treating in patients suffering from advanced neuroendocrine and gastroenteropancreatic tumors such as neuroblastomas. This is expected to drive the South & Central America radiopharmaceutical theranostics market during the forecast period.

On the contrary, regulatory challenges for approval of radiopharmaceutical theranostics hurdles the growth of South & Central America radiopharmaceutical theranostics market. 

Based on product type, the South & Central America radiopharmaceutical theranostics market is categorized into alpha emitters, beta emitters, and positron emission tomography (PET) tracers. The positron emission tomography (PET) tracers segment held 42.9% market share in 2022, amassing US$ 55.60 million. It is projected to garner US$ 103.68 million by 2028 to expand at 10.9% CAGR during 2022–2028.

Based on radioisotope, the South & Central America radiopharmaceutical theranostics market is categorized into technetium-99, gallium-68, iodine-131, iodine-123, fluorine-18 (18F), yttrium 90 (Y-90), Lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held 26.4% market share in 2022, amassing US$ 34.15 million. It is projected to garner US$ 65.06 million by 2028 to expand at 11.3% CAGR during 2022–2028.

Based on source, the South & Central America radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held 63.8% market share in 2022, amassing US$ 82.66 million. It is projected to garner US$ 157.69 million by 2028 to expand at 11.4% CAGR during 2022–2028.

Based on application, the South & Central America radiopharmaceutical theranostics market is bifurcated into targeted therapeutic [Rx] and Companion Diagnostic [CDx]. The targeted therapeutic [Rx] segment held 61.9% market share in 2022, amassing US$ 80.09 million. It is projected to garner US$ 146.63 million by 2028 to expand at 10.6% CAGR during 2022–2028.

Based on indication, the South & Central America radiopharmaceutical theranostics market is categorized into oncology, cardiology, neurology, and others. The oncology segment held 64.6% market share in 2022, amassing US$ 83.70 million. It is projected to garner US$ 156.23 million by 2028 to expand at 11.0% CAGR during 2022–2028.

Based on end user, the South & Central America radiopharmaceutical theranostics market is categorized into hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held 36.1% market share in 2022, amassing US$ 46.68 million. It is projected to garner US$ 82.91 million by 2028 to expand at 10.0% CAGR during 2022–2028.

Based on country, the South & Central America radiopharmaceutical theranostics market has been categorized into Brazil, Argentina, and the Rest of South & Central America.  Our regional analysis states that Brazil captured 61.4% share of South & Central America radiopharmaceutical theranostics market in 2022. It was assessed at US$ 79.51 million in 2022 and is likely to hit US$ 144.24 million by 2028, exhibiting a CAGR of 10.4% during 2022–2028.            

Key players operating in the South & Central America radiopharmaceutical theranostics market are Bayer AG; Curium; Telix Pharmaceuticals Ltd.; and Siemens Healthineers among others.

• In Oct 2021, Curium Initiates ECLIPSE, a Phase 3 Clinical Trial for Its Investigational Lu 177 PSMA I&T.
• In Feb 2022, Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com